Short-Course Induction Treatment with Intrathecal Amphotericin B Lipid Emulsion for HIV Infected Patients with Cryptococcal Meningitis

Cryptococcal meningitis (CM) is a common cause of death among HIV infected patients in developing countries, especially in sub-Saharan Africa. In this observational HIV cohort study in a resource-limited setting in India, we compared the standard two-week intravenous amphotericin B deoxycholate (AmB...

Full description

Saved in:
Bibliographic Details
Main Authors: Gerardo Alvarez-Uria, Manoranjan Midde, Raghavakalyan Pakam, Pradeep Sukumar Yalla, Praveen Kumar Naik, Raghuprakash Reddy
Format: Article
Language:English
Published: Wiley 2015-01-01
Series:Journal of Tropical Medicine
Online Access:http://dx.doi.org/10.1155/2015/864271
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1832562932821524480
author Gerardo Alvarez-Uria
Manoranjan Midde
Raghavakalyan Pakam
Pradeep Sukumar Yalla
Praveen Kumar Naik
Raghuprakash Reddy
author_facet Gerardo Alvarez-Uria
Manoranjan Midde
Raghavakalyan Pakam
Pradeep Sukumar Yalla
Praveen Kumar Naik
Raghuprakash Reddy
author_sort Gerardo Alvarez-Uria
collection DOAJ
description Cryptococcal meningitis (CM) is a common cause of death among HIV infected patients in developing countries, especially in sub-Saharan Africa. In this observational HIV cohort study in a resource-limited setting in India, we compared the standard two-week intravenous amphotericin B deoxycholate (AmBd) (Regimen I) with one week of intravenous AmBd along with daily therapeutic lumbar punctures and intrathecal AmB lipid emulsion (Regimen II) during the intensive phase of CM treatment. 78 patients received Regimen I and 45 patients received Regimen II. After adjustment for baseline characteristics (gender, age, altered mental status or seizures at presentation, CD4 cell count, white blood cells, cerebrospinal fluid white cells, and haemoglobin), the use of Regimen II was associated with a significant relative risk reduction in mortality (adjusted hazard ratio 0.4, 95% confidence interval, 0.22–0.76) and 26.7% absolute risk reduction (95% confidence interval, 9.9–43.5) at 12 weeks. The use of Regimen II resulted in lower costs of drugs and hospital admission days. Since the study is observational in nature, we should be cautious about our results. However, the good tolerability of intrathecal administration of AmB lipid emulsion and the clinically important mortality reduction observed with the short-course induction treatment warrant further research, ideally through a randomized clinical trial.
format Article
id doaj-art-299a2983bcd949549be97a47827befa2
institution Kabale University
issn 1687-9686
1687-9694
language English
publishDate 2015-01-01
publisher Wiley
record_format Article
series Journal of Tropical Medicine
spelling doaj-art-299a2983bcd949549be97a47827befa22025-02-03T01:21:20ZengWileyJournal of Tropical Medicine1687-96861687-96942015-01-01201510.1155/2015/864271864271Short-Course Induction Treatment with Intrathecal Amphotericin B Lipid Emulsion for HIV Infected Patients with Cryptococcal MeningitisGerardo Alvarez-Uria0Manoranjan Midde1Raghavakalyan Pakam2Pradeep Sukumar Yalla3Praveen Kumar Naik4Raghuprakash Reddy5Department of Infectious Diseases, RDT Bathalapalli Hospital, Kadiri Road, Bathalapalli 515661, IndiaDepartment of Infectious Diseases, RDT Bathalapalli Hospital, Kadiri Road, Bathalapalli 515661, IndiaDepartment of Infectious Diseases, RDT Bathalapalli Hospital, Kadiri Road, Bathalapalli 515661, IndiaDepartment of Infectious Diseases, RDT Bathalapalli Hospital, Kadiri Road, Bathalapalli 515661, IndiaDepartment of Infectious Diseases, RDT Bathalapalli Hospital, Kadiri Road, Bathalapalli 515661, IndiaDepartment of Microbiology, RDT Bathalapalli Hospital, Kadiri Road, Bathalapalli 515661, IndiaCryptococcal meningitis (CM) is a common cause of death among HIV infected patients in developing countries, especially in sub-Saharan Africa. In this observational HIV cohort study in a resource-limited setting in India, we compared the standard two-week intravenous amphotericin B deoxycholate (AmBd) (Regimen I) with one week of intravenous AmBd along with daily therapeutic lumbar punctures and intrathecal AmB lipid emulsion (Regimen II) during the intensive phase of CM treatment. 78 patients received Regimen I and 45 patients received Regimen II. After adjustment for baseline characteristics (gender, age, altered mental status or seizures at presentation, CD4 cell count, white blood cells, cerebrospinal fluid white cells, and haemoglobin), the use of Regimen II was associated with a significant relative risk reduction in mortality (adjusted hazard ratio 0.4, 95% confidence interval, 0.22–0.76) and 26.7% absolute risk reduction (95% confidence interval, 9.9–43.5) at 12 weeks. The use of Regimen II resulted in lower costs of drugs and hospital admission days. Since the study is observational in nature, we should be cautious about our results. However, the good tolerability of intrathecal administration of AmB lipid emulsion and the clinically important mortality reduction observed with the short-course induction treatment warrant further research, ideally through a randomized clinical trial.http://dx.doi.org/10.1155/2015/864271
spellingShingle Gerardo Alvarez-Uria
Manoranjan Midde
Raghavakalyan Pakam
Pradeep Sukumar Yalla
Praveen Kumar Naik
Raghuprakash Reddy
Short-Course Induction Treatment with Intrathecal Amphotericin B Lipid Emulsion for HIV Infected Patients with Cryptococcal Meningitis
Journal of Tropical Medicine
title Short-Course Induction Treatment with Intrathecal Amphotericin B Lipid Emulsion for HIV Infected Patients with Cryptococcal Meningitis
title_full Short-Course Induction Treatment with Intrathecal Amphotericin B Lipid Emulsion for HIV Infected Patients with Cryptococcal Meningitis
title_fullStr Short-Course Induction Treatment with Intrathecal Amphotericin B Lipid Emulsion for HIV Infected Patients with Cryptococcal Meningitis
title_full_unstemmed Short-Course Induction Treatment with Intrathecal Amphotericin B Lipid Emulsion for HIV Infected Patients with Cryptococcal Meningitis
title_short Short-Course Induction Treatment with Intrathecal Amphotericin B Lipid Emulsion for HIV Infected Patients with Cryptococcal Meningitis
title_sort short course induction treatment with intrathecal amphotericin b lipid emulsion for hiv infected patients with cryptococcal meningitis
url http://dx.doi.org/10.1155/2015/864271
work_keys_str_mv AT gerardoalvarezuria shortcourseinductiontreatmentwithintrathecalamphotericinblipidemulsionforhivinfectedpatientswithcryptococcalmeningitis
AT manoranjanmidde shortcourseinductiontreatmentwithintrathecalamphotericinblipidemulsionforhivinfectedpatientswithcryptococcalmeningitis
AT raghavakalyanpakam shortcourseinductiontreatmentwithintrathecalamphotericinblipidemulsionforhivinfectedpatientswithcryptococcalmeningitis
AT pradeepsukumaryalla shortcourseinductiontreatmentwithintrathecalamphotericinblipidemulsionforhivinfectedpatientswithcryptococcalmeningitis
AT praveenkumarnaik shortcourseinductiontreatmentwithintrathecalamphotericinblipidemulsionforhivinfectedpatientswithcryptococcalmeningitis
AT raghuprakashreddy shortcourseinductiontreatmentwithintrathecalamphotericinblipidemulsionforhivinfectedpatientswithcryptococcalmeningitis